FY2025 EPS Forecast for Solid Biosciences Boosted by Analyst

Key Points

• Analyst Cantor Fitzgerald has raised its FY2025 EPS estimate for Solid Biosciences to ($1.86) per share from a previous estimate of ($2.06), maintaining an "Overweight" rating and a $16 target price.
• The company reported a quarterly EPS of ($0.42), exceeding analysts' consensus expectation of ($0.51) by $0.09.
• Solid Biosciences' current stock has a consensus rating of "Buy," with several analysts setting target prices between $14 and $20.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for shares of Solid Biosciences in a report released on Wednesday, August 13th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($1.86) for the year, up from their previous estimate of ($2.06). Cantor Fitzgerald has a "Overweight" rating and a $16.00 price objective on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. Cantor Fitzgerald also issued estimates for Solid Biosciences' FY2026 earnings at ($1.93) EPS.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.09.

Several other research firms have also recently weighed in on SLDB. Piper Sandler cut their price objective on shares of Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating for the company in a research report on Friday, May 16th. Wall Street Zen upgraded shares of Solid Biosciences from a "sell" rating to a "hold" rating in a report on Saturday. Barclays decreased their target price on shares of Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating for the company in a research report on Friday, May 16th. Citigroup initiated coverage on shares of Solid Biosciences in a research report on Thursday, June 26th. They set a "buy" rating and a $14.00 price objective for the company. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Solid Biosciences from $15.00 to $13.00 and set an "overweight" rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Solid Biosciences currently has an average rating of "Buy" and a consensus price target of $15.00.

Solid Biosciences Trading Down 1.3%

Shares of NASDAQ:SLDB traded down $0.08 on Friday, hitting $6.03. The company had a trading volume of 858,887 shares, compared to its average volume of 1,377,243. The stock has a 50 day moving average price of $5.65 and a 200 day moving average price of $4.47. Solid Biosciences has a 1-year low of $2.41 and a 1-year high of $10.37. The stock has a market cap of $469.56 million, a price-to-earnings ratio of -2.15 and a beta of 2.44.

Hedge Funds Weigh In On Solid Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc boosted its position in shares of Solid Biosciences by 208.6% during the second quarter. Legal & General Group Plc now owns 6,011 shares of the company's stock valued at $29,000 after buying an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Solid Biosciences by 205.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company's stock worth $33,000 after acquiring an additional 4,534 shares in the last quarter. CWM LLC raised its holdings in Solid Biosciences by 15,188.5% during the 1st quarter. CWM LLC now owns 7,950 shares of the company's stock valued at $29,000 after buying an additional 7,898 shares during the period. Corton Capital Inc. bought a new position in Solid Biosciences in the 4th quarter valued at $41,000. Finally, Pallas Capital Advisors LLC bought a new position in Solid Biosciences in the 2nd quarter valued at $54,000. Institutional investors own 81.46% of the company's stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.